Hyphens Pharma Licenses Cerapro MED Skin Cream for Six European Markets

Hyphens Pharma Licenses Cerapro MED Skin Cream

Hyphens Pharma International Limited, a leading specialty pharmaceutical and consumer healthcare group based in Singapore, has recently made significant strides in the dermatological field. They have entered into an agreement with Louis Widmer SA, a renowned Swiss cosmetics and pharmaceuticals company, to out-license their innovative product, Cerapro® MED Skin Barrier Cream. This agreement allows for the commercialization of Cerapro across six European countries: Switzerland, Liechtenstein, Austria, Belgium, Luxembourg, and the Netherlands.

What is Cerapro?

Cerapro® is a patented skin barrier cream specifically designed to lower skin pH and assist in the treatment of atopic dermatitis, a chronic skin condition that affects millions globally. This disorder is characterized by dry, itchy skin and can be particularly challenging for both children and adults. Cerapro® has gained approval as a CE-marked medical device under the stringent European Medical Device Regulation (MDR), representing a new opportunity for effective treatment.

The formulation of Cerapro® stands out as it not only addresses the elevated skin pH levels often associated with eczema but also plays a crucial role in restoring the skin barrier. Lowering skin pH can enhance the skin’s natural antimicrobial defenses, making it an appealing option for patients seeking relief.

Agreement Details

Under the terms of the licensing agreement, Hyphens Pharma will receive an upfront fee along with customary royalties based on sales of Cerapro®. Louis Widmer, which has earned a reputation for producing high-quality dermatological products since 1960, will take on the task of promoting and commercializing Cerapro® among dermatologists and pediatricians in the targeted markets.

This collaboration aligns with the vision of both firms to provide scientifically-backed products that aim to improve patient outcomes in dermatological health. As Mr. Lim See Wah, Chairman and CEO of Hyphens Pharma, shared, "This milestone partnership with Louis Widmer underscores our commitment to innovation and patient care. We believe that by leveraging Louis Widmer's expertise and presence in dermatology, we can effectively introduce Cerapro® to patients across Europe."

The Importance of This Partnership

Annemarie Widmer, CEO of Louis Widmer, expressed her excitement about this collaboration, stating, "We are thrilled to partner with Hyphens Pharma to introduce Cerapro® to our markets, delivering a clinically proven solution for atopic dermatitis to patients. Cerapro® will be a key product in our Remederm line, which leads in Europe for skincare addressing dry and atopic skin issues."

Both companies aim to utilize their strengths to ensure that the product reaches the walls of various healthcare institutions and clinics, offering immediate relief to patients suffering from dermatitis.

About Hyphens Pharma

Hyphens Pharma International Limited operates not only within Singapore but also maintains a presence in Malaysia, Vietnam, Indonesia, and the Philippines. The group encompasses five key entities, including Hyphens Pharma, DocMed Technology, Ocean Health, Novem, and Ardence Aesthetics, covering the realms of Pharmaceuticals, Medical Aesthetics, Proprietary Brands, and Digital Platform E-Pharmacy. Their commitment to enhancing patients’ quality of life through innovative products continues to be at the forefront of their operations.

For anyone dealing with the challenges of atopic dermatitis, the Cerapro® MED Skin Barrier Cream could represent a transformative development in their treatment options, especially as it becomes available in more regions.

About Louis Widmer SA

Louis Widmer SA is celebrated for its high-quality skin care and dermatology products and has remained dedicated to sustainability and innovation since its inception in 1960. With a broad expertise in areas such as dry skin, acne, pigmentation disorders, and anti-aging, their focus on developing effective and safe treatments aligns well with the needs of patients.

As Hyphens Pharma and Louis Widmer embark on this joint venture, the potential for improved care for individuals suffering from skin conditions looks promising. With a science-backed approach and a commitment to quality, both companies are poised to make significant impacts in the dermatology field across Europe.